<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684359</url>
  </required_header>
  <id_info>
    <org_study_id>PRACTICE I</org_study_id>
    <nct_id>NCT00684359</nct_id>
  </id_info>
  <brief_title>Platelet Reactivity After Cessation of Clopid in the Setting of Coronary Stent Implantation I: PRACTICE I</brief_title>
  <acronym>PRACTICE I</acronym>
  <official_title>Platelet Reactivity After Cessation of Clopid in the Setting of Coronary Stent Implantation I: PRACTICE I</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single center randomized parallel group study to determine if:&#xD;
&#xD;
        1. there is a temporary increase in platelet reactivity after abrupt discontinuation of&#xD;
           clopidogrel due to a potential rebound phenomenon.&#xD;
&#xD;
        2. the effect of sudden discontinuation of clopidogrel 6 months post coronary angioplasty&#xD;
           with adjunct drug eluting stent implantation compared to 12 month continuation of&#xD;
           clopidogrel on platelet reactivity. And the association with MACE up to 12 months post&#xD;
           coronary angioplasty.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if there is a temporary increase in platelet reactivity after abrupt discontinuation of clopidogrel due to a potential rebound phenomenon</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine what the effect of sudden discontinuation of clopidogrel 6 months post coronary angioplasty with adjunct drug eluting stent implantation compared to 12 month continuation of clopidogrel on platelet reactivity.</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Coronary Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients, male or female, &gt; 18 years of age; who are scheduled for an elective PCI with a&#xD;
        drug eluting stent; willing to return for all required follow up visit and live/work within&#xD;
        a 60 mile radius of the Washington Hospital Center.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients, male or female, &gt; 18 years of age,&#xD;
&#xD;
          -  Patients who are scheduled for an elective PCI with a drug eluting stent&#xD;
&#xD;
          -  Patients willing to return for all required follow up visits.&#xD;
&#xD;
          -  Patients live/work within a 60 mile radius of the Washington Hospital Center.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has experienced an acute myocardial infarction within the preceding 48 hours&#xD;
             of the subsequent angioplasty.&#xD;
&#xD;
          -  Unprotected left main coronary disease with &gt;50% stenosis;&#xD;
&#xD;
          -  Patients with renal failure requiring dialysis;&#xD;
&#xD;
          -  Patients with a documented ejection fraction &lt; 30 percent at the time of subsequent&#xD;
             PCI;&#xD;
&#xD;
          -  Patient with a life expectancy less than 12 months or malignancy.&#xD;
&#xD;
          -  Known allergies to aspirin or clopidogrel bisulfate (PlavixR) and that cannot be&#xD;
             medically managed;&#xD;
&#xD;
          -  Planned surgery or other indication for requiring the cessation of clopidogrel within&#xD;
             12 months of PCI;&#xD;
&#xD;
          -  Any significant medical condition which in the investigator's opinion may interfere&#xD;
             with the patient's optimal participation in the study.&#xD;
&#xD;
          -  Patients with known history of bleeding diathesis;&#xD;
&#xD;
          -  Prothrombin time &gt;1.5 times control; coumadin therapy&#xD;
&#xD;
          -  Platelet count &lt;100 000/mm3;&#xD;
&#xD;
          -  Hematocrit &lt;25%;&#xD;
&#xD;
          -  Creatinine &gt;4.0 mg/dL;&#xD;
&#xD;
          -  Thienopyridine use within 5 days of enrollment&#xD;
&#xD;
          -  Glycoprotein (GP) IIb/IIIa use within 8 hours of enrollment or any indication were the&#xD;
             operator will require GP IIb/IIIa inhibitor use during the hospitalization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ron Waksman, MD, Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>May 21, 2008</study_first_submitted>
  <study_first_submitted_qc>May 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2008</study_first_posted>
  <last_update_submitted>May 28, 2010</last_update_submitted>
  <last_update_submitted_qc>May 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2010</last_update_posted>
  <responsible_party>
    <name_title>Ron Waksman, MD</name_title>
    <organization>MedStar Research Institute/Cardiovascular Research Institute</organization>
  </responsible_party>
  <keyword>Patients having PCI with a drug eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

